Published in Acta Oncol on January 01, 2006
Immunologic correlates of the abscopal effect in a patient with melanoma. N Engl J Med (2012) 8.46
Fractionated but not single-dose radiotherapy induces an immune-mediated abscopal effect when combined with anti-CTLA-4 antibody. Clin Cancer Res (2009) 4.58
Combining radiotherapy and cancer immunotherapy: a paradigm shift. J Natl Cancer Inst (2013) 3.07
Irradiation and anti-PD-L1 treatment synergistically promote antitumor immunity in mice. J Clin Invest (2014) 3.06
An abscopal response to radiation and ipilimumab in a patient with metastatic non-small cell lung cancer. Cancer Immunol Res (2013) 2.30
Radiation as an immunological adjuvant: current evidence on dose and fractionation. Front Oncol (2012) 1.76
Radiation and immunotherapy: a synergistic combination. J Clin Invest (2013) 1.44
The tumour microenvironment after radiotherapy: mechanisms of resistance and recurrence. Nat Rev Cancer (2015) 1.43
Targeting immune suppressing myeloid-derived suppressor cells in oncology. Crit Rev Oncol Hematol (2010) 1.25
The abscopal effect of local radiotherapy: using immunotherapy to make a rare event clinically relevant. Cancer Treat Rev (2015) 1.22
Combining radiation and immunotherapy for synergistic antitumor therapy. Curr Opin Mol Ther (2009) 1.03
Combinations of immunotherapy and radiation in cancer therapy. Front Oncol (2014) 1.01
Immunogenic tumor cell death induced by chemoradiotherapy: molecular mechanisms and a clinical translation. Cell Death Dis (2013) 0.93
Targeting the inhibitory receptor CTLA-4 on T cells increased abscopal effects in murine mesothelioma model. Oncotarget (2015) 0.93
Role of radiation therapy in the management of renal cell cancer. Cancers (Basel) (2011) 0.89
How does ionizing irradiation contribute to the induction of anti-tumor immunity? Front Oncol (2012) 0.88
Local control rates of metastatic renal cell carcinoma (RCC) to the bone using stereotactic body radiation therapy: Is RCC truly radioresistant? Pract Radiat Oncol (2015) 0.87
Phase Ib study evaluating a self-adjuvanted mRNA cancer vaccine (RNActive®) combined with local radiation as consolidation and maintenance treatment for patients with stage IV non-small cell lung cancer. BMC Cancer (2014) 0.83
The potential of radiotherapy to enhance the efficacy of renal cell carcinoma therapy. Oncoimmunology (2015) 0.83
Immune biomarkers of treatment failure for a patient on a phase I clinical trial of pembrolizumab plus radiotherapy. J Hematol Oncol (2016) 0.79
Short communication: timeline of radiation-induced kidney function loss after stereotactic ablative body radiotherapy of renal cell carcinoma as evaluated by serial (99m)Tc-DMSA SPECT/CT. Radiat Oncol (2014) 0.78
Fractionated Radiotherapy with 3 x 8 Gy Induces Systemic Anti-Tumour Responses and Abscopal Tumour Inhibition without Modulating the Humoral Anti-Tumour Response. PLoS One (2016) 0.78
Immune Modulation by Androgen Deprivation and Radiation Therapy: Implications for Prostate Cancer Immunotherapy. Cancers (Basel) (2017) 0.77
Radiation for Awakening the Dormant Immune System, a Promising Challenge to be Explored. Front Immunol (2014) 0.77
Linking the history of radiation biology to the hallmarks of cancer. Radiat Res (2014) 0.76
Immunotherapy for neuro-oncology: the critical rationale for combinatorial therapy. Neuro Oncol (2015) 0.75
Challenges of Using High-Dose Fractionation Radiotherapy in Combination Therapy. Front Oncol (2016) 0.75
Tumor-targeted IL-12 combined with local irradiation leads to systemic tumor control via abscopal effects in vivo. Oncoimmunology (2017) 0.75
Emerging Therapies for Stage III Non-Small Cell Lung Cancer: Stereotactic Body Radiation Therapy and Immunotherapy. Front Oncol (2017) 0.75
Outcome in a prospective phase II trial of medically inoperable stage I non-small-cell lung cancer patients treated with stereotactic body radiotherapy. J Clin Oncol (2009) 3.66
Thymidylate synthase expression in colorectal cancer: a prognostic and predictive marker of benefit from adjuvant fluorouracil-based chemotherapy. J Clin Oncol (2002) 2.28
CD4+CD25high T cells are enriched in the tumor and peripheral blood of prostate cancer patients. J Immunol (2006) 2.18
The role of radiotherapy in treatment of stage I non-small cell lung cancer. Lung Cancer (2003) 1.96
Stereotactic radiotherapy of primary lung cancer and other targets: results of consultant meeting of the International Atomic Energy Agency. Int J Radiat Oncol Biol Phys (2011) 1.94
Phase 1 study results of the type II glycoengineered humanized anti-CD20 monoclonal antibody obinutuzumab (GA101) in B-cell lymphoma patients. Blood (2012) 1.89
Detection of thymidylate synthase expression in lymph node metastases of colorectal cancer can improve the prognostic information. J Clin Oncol (2005) 1.53
Skin electroporation: effects on transgene expression, DNA persistence and local tissue environment. PLoS One (2009) 1.46
Proteomic analysis of tumor establishment and growth in the B16-F10 mouse melanoma model. J Proteome Res (2006) 1.46
Extracranial stereotactic radiotherapy for primary and metastatic renal cell carcinoma. Radiother Oncol (2005) 1.45
A prospective Phase II trial of using extracranial stereotactic radiotherapy in primary and metastatic renal cell carcinoma. Acta Oncol (2006) 1.41
[Do Norwegian cancer patients receive the care they deserve?]. Tidsskr Nor Laegeforen (2006) 1.39
Enhancement of cellular immune response to a prostate cancer DNA vaccine by intradermal electroporation. Mol Ther (2005) 1.29
Factors important for efficacy of stereotactic body radiotherapy of medically inoperable stage I lung cancer. A retrospective analysis of patients treated in the Nordic countries. Acta Oncol (2006) 1.29
Stereotactic body radiotherapy for medically inoperable patients with stage I non-small cell lung cancer - a first report of toxicity related to COPD/CVD in a non-randomized prospective phase II study. Radiother Oncol (2008) 1.20
Stereotactic body radiotherapy of primary and metastatic renal lesions for patients with only one functioning kidney. Acta Oncol (2008) 1.17
Optimization of skin electroporation in mice to increase tolerability of DNA vaccine delivery to patients. Mol Ther (2009) 1.15
SBRT of lung tumours: Monte Carlo simulation with PENELOPE of dose distributions including respiratory motion and comparison with different treatment planning systems. Phys Med Biol (2007) 1.11
Genomic profile of breast cancer. Expert Rev Pharmacoecon Outcomes Res (2015) 1.09
Toxicity after reirradiation of pulmonary tumours with stereotactic body radiotherapy. Radiother Oncol (2011) 1.08
Gene-modified dendritic cells for immunotherapy against cancer. Med Oncol (2002) 1.08
Mature dendritic cells are protected from Fas/CD95-mediated apoptosis by upregulation of Bcl-X(L). Cancer Immunol Immunother (2002) 1.05
Role of gross tumor volume on outcome and of dose parameters on toxicity of patients undergoing chemoradiotherapy for locally advanced non-small cell lung cancer. Med Oncol (2005) 1.00
Zoledronic acid modulates antitumoral responses of prostate cancer-tumor associated macrophages. Cancer Immunol Immunother (2008) 1.00
HER-2/neu mediated down-regulation of MHC class I antigen processing prevents CTL-mediated tumor recognition upon DNA vaccination in HLA-A2 transgenic mice. Cancer Immunol Immunother (2008) 1.00
Tumor escape mechanisms in prostate cancer. Cancer Immunol Immunother (2005) 1.00
Induction of PSA-specific CTLs and anti-tumor immunity by a genetic prostate cancer vaccine. Prostate (2005) 0.97
Immune monitoring in a phase 1 trial of a PSA DNA vaccine in patients with hormone-refractory prostate cancer. J Immunother (2005) 0.94
Identification of an immunodominant H-2D(b)-restricted CTL epitope of human PSA. Prostate (2005) 0.92
Bevacizumab: direct anti-VEGF therapy in renal cell carcinoma. Expert Rev Anticancer Ther (2008) 0.92
The impact of the 21-gene Recurrence Score assay on clinical decision-making in node-positive (up to 3 positive nodes) estrogen receptor-positive breast cancer patients. Breast Cancer Res Treat (2013) 0.91
NTCP modelling of lung toxicity after SBRT comparing the universal survival curve and the linear quadratic model for fractionation correction. Acta Oncol (2011) 0.90
Tumor-specific bacteriophages induce tumor destruction through activation of tumor-associated macrophages. J Immunol (2009) 0.90
Radiosurgery for recurring liver metastases after hepatectomy. Hepatogastroenterology (2003) 0.88
Retrospective cohort study of bronchial doses and radiation-induced atelectasis after stereotactic body radiation therapy of lung tumors located close to the bronchial tree. Int J Radiat Oncol Biol Phys (2013) 0.88
Allogeneic tumor-dendritic cell fusion vaccines for generation of broad prostate cancer T-cell responses. Med Oncol (2004) 0.86
Distribution of Foxp3-, CD4- and CD8-positive lymphocytic cells in benign and malignant prostate tissue. APMIS (2010) 0.86
Mature dendritic cells induce tumor-specific type 1 regulatory T cells. J Immunother (2005) 0.86
Tumor specific phage particles promote tumor regression in a mouse melanoma model. Cancer Immunol Immunother (2006) 0.86
Expression of PDX-1 in prostate cancer, prostatic intraepithelial neoplasia and benign prostatic tissue. APMIS (2008) 0.84
Liver, renal, and retroperitoneal tumors: stereotactic radiotherapy. Front Radiat Ther Oncol (2007) 0.84
Current perspectives in the treatment of advanced prostate cancer. Med Oncol (2007) 0.84
Is repeated radiosurgery an alternative to staged radiosurgery for very large brain arteriovenous malformations? J Neurosurg (2007) 0.83
AAA and PBC calculation accuracy in the surface build-up region in tangential beam treatments. Phantom and breast case study with the Monte Carlo code PENELOPE. Radiother Oncol (2009) 0.83
Interference of macrophage migration inhibitory factor expression in a mouse melanoma inhibits tumor establishment by up-regulating thrombospondin-1. Mol Cancer Res (2007) 0.83
DNA vaccine coding for the rhesus prostate specific antigen delivered by intradermal electroporation in patients with relapsed prostate cancer. Vaccine (2013) 0.83
Recombinant adenovirus vector activates and protects human monocyte-derived dendritic cells from apoptosis. Hum Gene Ther (2002) 0.83
Priming of CD8+ T-cell responses after DNA immunization is impaired in TLR9- and MyD88-deficient mice. Vaccine (2007) 0.83
Prostasin, a potential tumor marker in ovarian cancer--a pilot study. Clinics (Sao Paulo) (2009) 0.82
DNA vaccination for prostate cancer. Methods Mol Biol (2008) 0.81
Long-term results after fractionated radiation therapy for large brain arteriovenous malformations. Neurosurgery (2005) 0.80
Survival and tumour control probability in tumours with heterogeneous oxygenation: a comparison between the linear-quadratic and the universal survival curve models for high doses. Acta Oncol (2014) 0.80
Correlation between HLA-A2 gene frequency, latitude, ovarian and prostate cancer mortality rates. Med Oncol (2004) 0.80
Economic evaluations of leukemia: a review of the literature. Int J Technol Assess Health Care (2007) 0.80
Comparison of PSA-specific CD8+ CTL responses and antitumor immunity generated by plasmid DNA vaccines encoding PSA-HSP chimeric proteins. Cancer Immunol Immunother (2004) 0.79
Stereotactic body radiation therapy for early non-small cell lung cancer. Front Radiat Ther Oncol (2009) 0.79
Nonviral and viral gene transfer into different subsets of human dendritic cells yield comparable efficiency of transfection. J Immunother (2002) 0.78
Prediction of AVM obliteration after stereotactic radiotherapy using radiobiological modelling. Phys Med Biol (2002) 0.78
Presence and specificity of tumor associated lymphocytes from ascites fluid in prostate cancer. Prostate (2005) 0.78
The impact of fractionation in SBRT: analysis with the linear quadratic model and the universal survival curve model. Acta Oncol (2013) 0.78
Treatment fractionation for stereotactic radiotherapy of lung tumours: a modelling study of the influence of chronic and acute hypoxia on tumour control probability. Radiat Oncol (2014) 0.77
[18 F]FDG-PET imaging is an early non-invasive pharmacodynamic biomarker for a first-in-class dual MEK/Raf inhibitor, RO5126766 (CH5126766), in preclinical xenograft models. EJNMMI Res (2013) 0.77
Palliation of bone pain in prostate cancer using chemotherapy and strontium-89. A randomized phase II study. J Pain Symptom Manage (2005) 0.77
Curative stereotactic body radiotherapy for liver malignancy. Med Oncol (2008) 0.77
Long-term results of a prospective phase II trial of medically inoperable stage I NSCLC treated with SBRT - the Nordic experience. Acta Oncol (2015) 0.76
A retrospective study of SBRT of metastases in patients with primary sarcoma. Med Oncol (2012) 0.76
A modified epitope identified for generation and monitoring of PSA-specific T cells in patients on early phases of PSA-based immunotherapeutic protocols. Vaccine (2009) 0.76
Molecular cytogenetic characterization shows higher genetic homogeneity in conventional renal cell carcinoma compared to other kidney cancers. Int J Oncol (2004) 0.76
Plasmid DNA vaccines against cancer: cytotoxic T-lymphocyte induction against tumor antigens. Expert Rev Vaccines (2005) 0.76
Undetectable late hepatic sequelae after hypofractionated stereotactic radiotherapy for liver tumors. Med Oncol (2010) 0.76
Thymidylate synthase expression in rectal cancer and proliferation, assessed by cyclin A and Ki-67 expression. Anticancer Res (2003) 0.76
Calculation of isoeffective doses and the alpha/beta value by comparing results following radiosurgery and radiotherapy for arteriovenous malformations of the brain. J Neurosurg (2006) 0.75
Dummy run for a phase II study of stereotactic body radiotherapy of T1-T2 N0M0 medical inoperable non-small cell lung cancer. Acta Oncol (2006) 0.75
Expression of the signal transduction molecule zeta in peripheral and tumour-associated lymphocytes in Hodgkin's disease in relation to the Epstein-Barr virus status of the tumour cells. Br J Haematol (2002) 0.75
Risk of Acute Testicular Failure After Preoperative Radiotherapy for Rectal Cancer: A Prospective Cohort Study. Ann Surg (2016) 0.75
Expression of immunomodulating genes in prostate cancer and benign prostatic tissue. Anal Quant Cytol Histol (2009) 0.75
Monocyte enriched apheresis for preparation of dendritic cells (DC) to be used in cellular therapy. Transfus Apher Sci (2005) 0.75
Surgical displacement of risk organs to improve stereotactic radiotherapy for liver tumors. J Surg Oncol (2009) 0.75